Supplemental Table S1. Clinical outcomes before randomization period

Variables	Group A (10/10) (n=95)	Group B (10/5) (n=98)	All (n=193)	p Value
BARC bleedings				
Any bleeding, %	17 (17.9)	14 (14.3)	31 (16.1)	0.495
Type 1, %	16 (16.8)	12 (12.2)	28 (14.5)	0.365
Type 2, %	1 (1.1)	2 (2.0)	3 (1.6)	0.579
Type 1 & Type 2, %	17 (17.9)	14 (14.3)	31 (16.1)	0.495
Type 3				
Type 3a, %	0 (0)	0 (0)	0 (0)	-
Type 3b, %	0 (0)	0 (0)	0 (0)	-
Type 3c, %	0 (0)	0 (0)	0 (0)	-
Type 4, %	0 (0)	0 (0)	0 (0)	-
Type 5				
Type 5a, %	0 (0)	0 (0)	0 (0)	-
Type 5b, %	0 (0)	0 (0)	0 (0)	-
Thrombotic events				
Non cardiac death	0 (0)	0 (0)	0 (0)	-
MACE	0 (0)	0 (0)	0 (0)	-
Cardiac death	0 (0)	0 (0)	0 (0)	-
Myocardial infarction	0 (0)	0 (0)	0 (0)	-
TIA or stroke	0 (0)	0 (0)	0 (0)	-
Definite stent thrombosis	1 (1.1)	0 (0)	1 (0.5)	0.309
Prasugrel discontinuation	0 (0)	0 (0)	0 (0)	-
Periprocedural MI*	9/66 (13.6)	4/71 (5.6)	13/137 (9.5)	0.110

Values are expressed as mean ± SD or n (%). BARC, Bleeding Academic Research Consortium; MI, Myocardial infarction; TIA, Transient Ischemic Attack. * The percentage is calculated on the UA/NSTEMI population. The definition of periprocedural myocardial infarction is in accordance with the "Third Universal Definition of Myocardial Infarction" (European Heart Journal 2012; 33: 2551–2567).

Supplemental Table S2. Pharmacodynamic findings

Variables	Group A (10/10) (n=77)	Group B (10/5) (n=75)	All (n=152)	p Value
LTA platelet function test (T_0)*				
ADP 10 µmol test value, %	34.4 ± 16.6	30.9 ± 15.5	32.7 ± 16.1	0.199
HRPR, %	1 (1.3)	1 (1.3)	2 (1.3)	0.982
LTA platelet function test (T_1)**				
ADP 10 µmol test value, %	47.5 ± 15.7	52.9 ± 15.5	50.1 ± 15.8	0.038
HRPR, %	4 (5.2)	10 (13.3)	14 (9.2)	0.083
DELTA ADP 10 % vs. T_0, mean (SD)	13.8 ± 14.7	23.5 ± 19.2	18.5 ± 17.7	<0.001
LTA platelet function test (T_2)***				
ADP 10 µmol test value, %	44.5 ±13.6	50.5 ± 15.8	47.4 ± 15.0	0.015
HRPR, %	2 (2.6)	10 (13.3)	12 (7.9)	0.014
DELTA ADP 10 % vs. T_0, mean (SD)	10.8 ± 16.1	21.1 ± 18.2	15.8 ± 17.9	<0.001

Values are expressed as mean ± SD or n (%). LTA, light transmittance aggregometry; ADP, adenosine diphosphate; HRPR, high residual platelet reactivity; * T_0 = after prasugrel loading dose; ** T_1 = 37 days; *** T_2 = 180 days.